Although there is As growing evidence that psychelic drugs can effectively severe mental health problems, especially in cases where traditional treatments have failed, they are always as for the disadvantages.

Their hallucinogenic effects can be frightening and overwhelming, with dosage sessions that last several hours. A good treatment is strongly ridiculous on the state of mind of the individual in a session and the environment in which then receive it. And although it is rare, psychedelics can sometimes worsen existing mental illness.

Mindstate Design Labs is part of a list of new companies aimed at making safer psychedelics by going up the classic “journey” associated with them. The company uses AI to help design psychic drugs that induce specific mental states without hallucinations, and its first compound seems promising.

“We have created the least psychedelic psychedelic who is psychoactive,” said CEO Dillan Dinardo. “It’s quite psychoactive, but there are no halucinations.”

Founded in 2021 and supported by Y combinator and the founders of Openai, Neuralink, Instacart, Coinbase and Twitch, Mindstate has built a set of AI models which connect the biochemical date of different psychactive drugs to more than 70,000 travel reports “compiled from sources – official clinical data and drugs for social media, social networks, Reds, reddit, and even the web.

Analysis by the platform of the way in which psyceques produce different effects led to the development of its first candidates for drugs, MSD-001, an oral formulation due to 5-Meo-Mipt, also known as rue Moxy. Phase The results of the trial shared with Wired, the drug was safe and well tolerated at five different doses in 47 healthy participants. He has also produced psychoactive effects without inducing a trap that folds, which, according to the company, is a validation of its AI platform.

Although emotions have reported emotions, associative thought, improved imagination and perceptual effects such as brighter colors, have not experienced hallucinations, self-espion, ocean liaison and other typical characteristics of a psychelic journey.

The company has measured the effects of the drug with validated scales used in psychchède research and asked participants subjective such as “Are you happy?” And “Are you sad?” The researchers also observed the movement of the eyes and the stability of the volunteers, and they carried out brain imagery before, during and after the psychoactive effects. Using this brain imaging data, the company was able to determine that the drug produced many of the same brain waves patterns associated with psilocybin and other first generation psychcherics. “The drug enters the brain and does what we want to do,” said Dinardo.

The psychoactive effects started with 30 minutes after the participants took the medication, with a cutting -edge intensity that makes fun of about the time and a half to two hours. The company does not report any serious adverse event.

The trial, which took place at the Center for Human Drug Research in the Netherlands, included a mixture of individuals who had tried the psychchèques in the past and others who had not done so.

Mindstate’s approach is based on the idea that a psychedelic “journey” may not be necessary for a therapeutic benefit. Psychedelics work on the seroton system of the brain by promoting neuroplasticity, which implies the growth of neurons and the formation of new connections. Some researchers believe that this skill with stimulated neuroplasticity, rather than hallucinogenic effects, is the key to the treatment of mental illness.